Psychedelics are the Next Big Thing in Mental Health. But is it Ethical to Profit from Them?
Psychedelics have long been used for spiritual and cultural purposes by indigenous peoples around the world. However, in recent years, psychedelics have gained attention in the medical and therapeutic fields due to their potential to treat mental health disorders such as depression and anxiety.
As the use of psychedelics for therapy gains popularity, controversy surrounding their commercialization has emerged. We will explore the debate surrounding the commercialization of psychedelics and its implications for access to care, profit, and cultural appropriation.
Accessibility of care is a crucial issue in the debate surrounding the commercialization of psychedelics. While the potential therapeutic benefits of psychedelics are promising, the high cost of therapy can exclude lower-income individuals from accessing this potentially life-changing treatment. Certainly practitioners deserve to be paid for their services, but monopolization could result in a situation where only a wealthy demographic can afford access to psychedelic therapy. Not only is this unjust and discriminatory, it violates the spirit in which many indigenous cultures hold regarding the use of these plant medicines.
Another issue that arises with the commercialization of psychedelics is the profit motive. Pharmaceutical companies may seek to patent and develop synthetic psychedelics or their derivatives, which could lead to the exclusion of natural versions such as the mushroom itself or the actual cactus the compound comes from. This could result in the monopolization of psychedelic therapy, leading to a lack of diversity in the treatments available, and potentially driving up the cost of care.
Indigenous people have brought many psychedelics to the west with their own ceremonies and rituals, which have been used for centuries for spiritual and cultural purposes. As Western medicine and science integrate psychedelics into their treatments, the potential for cultural appropriation arises. It is essential to consider the implications of using psychedelics outside of their cultural context and the potential impact on the indigenous communities who brought them to the west.
The potential for harm to indigenous cultures poses an additional issue to the commercialization of psychedelics. Many of these cultures have been using psychedelics in spiritual and medicinal contexts for centuries, long before western science began to study their effects. As psychedelics become more mainstream and are incorporated into western medicine, there is a risk of these cultures being exploited and disenfranchised.
For example, the peyote cactus has been used for centuries in Native American ceremonies. However, there are concerns that the commercialization could lead to the depletion of natural resources and a loss of cultural heritage. Additionally, there have been instances of non-Native individuals and organizations attempting to patent or trademark the use of peyote, which has been met with strong opposition from Native American communities.
The development of synthetic derivatives seems like it can offer several advantages over natural sources. For example, synthetic molecules can be produced more consistently and with greater purity, which can make it easier to standardize doses and minimize the risk of adverse effects. Synthetic derivatives can also be designed to have specific properties, such as longer or shorter durations of action, which can be helpful for tailoring treatment to individual patients.
However, there are also concerns that the commercialization and widespread use of synthetic derivatives could have negative consequences. One potential risk is that these molecules could be patented and sold at high prices, making them inaccessible to people who cannot afford them. This could result in a situation where only wealthy individuals have access to psychedelic assisted therapy, which could exacerbate existing disparities in healthcare access.
Another risk is synthetic derivatives could be used to displace natural sources of psychedelics, which are often used in traditional cultural contexts by indigenous peoples. The widespread adoption of synthetic molecules could lead to the loss of traditional knowledge and practices, and could undermine the cultural heritage of these communities.
It is important to acknowledge the potential risks and ethical concerns associated with the commercialization of psychedelics. However, it is also important to recognize the potential benefits that these substances could have in treating mental health conditions and improving overall well-being. Balancing these concerns and considerations will be a key challenge moving forward.
The commercialization of psychedelics poses significant ethical considerations. However, it is possible to create a balance between profit and accessibility to care. One potential solution is to support the responsible use of natural psychedelics in their traditional cultural context. Additionally, companies can partner with indigenous communities to develop and distribute psychedelics in a manner that respects cultural traditions and provides access to care for all.
The commercialization of psychedelics presents a complex set of issues and controversies. While the potential benefits of these substances in treating mental health conditions are promising, there are also concerns about accessibility of care, profit motives, and harm to indigenous cultures. It is important to approach these issues with careful consideration and to work towards solutions that prioritize patient care, honoring cultural heritage, and ethical practices.
H. Friedman, R. Gonzalez-Elizondo, and G. E. Bendezú-Harms, “Cultural variations in the use of psychedelics for spiritual purposes,” F1000Research, vol. 8, no. 522, 2019.
R. Carhart-Harris and M. J. Nutt, “Serotonin and brain function: a tale of two receptors,” Journal of Psychopharmacology, vol. 31, no. 9, pp. 1091–1120, 2017.
C. S. Grob et al., “Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer,” Archives of General Psychiatry, vol. 68, no. 1, pp. 71–78, 2011.
Ross, N. E., Regehr, C., & LeBlanc, S. (2018). Psychedelics and psychotherapy: A multidisciplinary perspective. Journal of Psychoactive Drugs, 50(5), 405-414.